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Outpatient Parenteral Antimicrobial Therapy in Pediatric
Medicaid Enrollees
Jennifer L. Goldman,1,2 Troy Richardson,3 Jason G. Newland,1,2 Brian Lee,1,2 Jeffrey S. Gerber,4 Matt Hall,3 Matthew Kronman,5 and Adam L. Hersh6
Children's Mercy Hospitals and Clinics, Kansas City, Missouri, 2University of Missouri-Kansas City, 3Children's Hospital Association, Overland Park, Kansas; 4Children's Hospital
of Philadelphia, Pennsylvania; 5Seattle Children's, Washington; and 6University of Utah School of Medicine, Salt Lake City
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Background. Outpatient parenteral antimicrobial therapy (OPAT) is overused in cases where highly bioavailable oral alternatives would be equally effective. However, the scope of OPAT use for children nationwide is poorly understood. Our objective was to
characterize OPAT use and clinical outcomes for a large population of pediatric Medicaid enrollees treated with OPAT.
Methods. We analyzed the Truven MarketScan Medicaid claims database between 2009 and 2012. An OPAT episode was identified
by capturing children with claims data indicating home infusion therapy for an intravenous antimicrobial. We characterized OPAT use
by describing patient demographics, diagnoses, and antimicrobials prescribed. We categorized an antimicrobial as highly bioavailable
if ≥80% systemic exposure was expected from the peroral dose. We also determined the percentage of OPAT recipients in whom a
follow-up healthcare encounter occurred during the OPAT episode in either the emergency department or as a hospital admission. We
reviewed the primary diagnoses associated with these healthcare encounters to determine whether it was related to OPAT.
Results. We identified 3433 OPAT episodes in 2687 patients. A total of 4774 antimicrobials were prescribed during these
episodes. Ceftriaxone and vancomycin were the most commonly prescribed antimicrobials. Highly bioavailable antimicrobials
accounted for 34% of antimicrobials used for OPAT. An emergency department visit or hospital admission occurred during 38% of
OPAT episodes, among which 61% were OPAT-related.
Conclusions. The high rate of medical encounters associated with OPAT in this cohort and the common prescribing of highly
bioavailable antimicrobials underscore the opportunities for antimicrobial stewardship of pediatric OPAT.
Keywords. outpatient parenteral antimicrobial therapy; pediatrics.

Outpatient parenteral antimicrobial therapy (OPAT) is the administration of intravenous (IV) antimicrobial medications outside of
the inpatient hospital setting. Outpatient parenteral antimicrobial therapy has been used for nearly 40 years to treat infections
requiring long-term antimicrobial use [1]. When considered relative to prolonged hospitalization, it is both cost-effective and relatively safe, resulting in extensive use both in adult and pediatric
medical care practices [2–5]. National registries serve as a useful
source in describing OPAT use; however, these data often lack
detailed information concerning OPAT in children [6, 7]. Data
from individual pediatric hospitals have shown that OPAT is most
frequently used to treat respiratory tract (including cystic fibrosis), musculoskeletal, bloodstream, intra-abdominal, skin and soft
tissue, urinary tract, and central nervous system infections [1, 8].
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Children receiving prolonged antimicrobial therapy, including OPAT, experience a high rate of adverse events [9]. Outpatient
parenteral antimicrobial therapy is overused, especially for conditions where highly bioavailable oral alternatives would be
equally effective such as acute osteomyelitis [10]. Overuse of
OPAT exposes children and their families to excess costs and
potentially avoidable catheter-related complications including
infection and thrombosis [5, 11, 12]. Some of these complications may result in hospital readmission or other unplanned
healthcare encounters including emergency department (ED)
visits. The high rate of hospital readmission for patients treated
with OPAT was recently highlighted in a study of adult patients,
but similar data for pediatric OPAT are sparse [13].
The objectives of this study were to characterize the most
commonly used antimicrobials for OPAT, the diagnoses treated
with OPAT, and healthcare use likely attributable to an OPAT
complication for a large population of US children.
METHODS
Data Source and Study Design

We analyzed data from the Truven MarketScan (Ann Arbor,
Michigan) Medicaid claims database between 2009 and 2012.
The MarketScan Medicaid Database contains the pooled
OPAT Use in Medicaid Enrollees • JPIDS 2017:6 (March) • 65

healthcare experience of approximately 6 million Medicaid
enrollees from multiple anonymous states. In 2009 the database
included 9 states, and in 2010–2012 12 states were included.
The database includes patient demographic and diagnostic
information, data on inpatient services received and outpatient
prescription drug claims, as well as information on enrollment,
long-term care, and other medical care.
Study Population and Diagnostic Categories

We included all Medicaid claims for children 0–18 years of
age. Outpatient claims with a healthcare common procedure
coding system (HCPCS) code indicating home infusion therapy [HIT; (S9494, S9497, S9500–504)], a current procedural
terminology (CPT) code indicating HIT (99601, 99602), or a
HCPCS code indicating HIT supplies (A4220–223, A4246–247,
E0776, E0779–781, E0791, S5497–498, S5501–502, S5517–518,
S5520–523) were considered HIT claims. The days between the
date service incurred on the initial HIT claim and the date service ended on the final HIT claim were used to identify a HIT
episode. Home infusion therapy claims with a gap of less than
30 days were considered to be part of the same HIT episode; if
a gap of 30 days or more existed between the date service ended
on 1 HIT claim and the date service was incurred for a subsequent HIT claim, the episodes were considered separate. Home
infusion therapy episodes were considered OPAT episodes
if either of the following were identified between the starting
date and ending date of a HIT episode: (1) a concomitant claim
with a HCPCS code indicating IV antimicrobial (Supplemental
Table 1) use or (2) a concomitant retail pharmacy claim indicating a fill for an IV antimicrobial. Finally, only OPAT episodes in
which patients were continuously enrolled in Medicaid during
the duration of the OPAT episode were considered for analysis.
All International Classification of Diseases, Ninth Revision,
Clinical Modification (ICD-9-CM) codes associated with the
OPAT episode were collected (Supplemental Table 2). The discharge diagnostic code occurring most frequently and concurrently during an OPAT episode was considered the primary
diagnosis. If ≥2 diagnoses occurred the same number of times,
all were included in the analysis resulting in greater than 1
diagnosis per episode. Nine hundred twenty-six unique primary ICD-9-CM codes were identified, and each diagnosis was
then grouped into 1 of 15 broader diagnostic categories based
on consensus by 2 authors (J. L. G. and A. L. H.): hematology/
oncology (H/O), gastrointestinal/genitourinary (GI/GU), cystic
fibrosis (CF), osteoarticular, pulmonary (excluding CF), central
nervous system (CNS), skin and soft tissue infection (SSTI),
bacteremia, endovascular/endocarditis, upper respiratory tract
(URI), urinary tract infection, surgical site, specific pathogen,
other, and unknown. The 15 diagnostic categories were created
in part by adapting from a previous study [14]. The pathogen
category was selected when the only available code was specific to an organism without additional codes providing further
66 • JPIDS 2017:6 (March) • Goldman et al

information (eg, 04112 for methicillin-resistant Staphylococcus
aureus).
Antimicrobial Use

For each OPAT episode, we determined the antimicrobial(s)
used. We defined highly bioavailable antimicrobials as those
with ≥80% systemic exposure from peroral dose [15], including
clindamycin, fluconazole, fluoroquinolones, linezolid, metronidazole, trimethoprim-sulfamethoxazole, and voriconazole. The
identification of highly bioavailable agents is important because
in some instances, these agents could be prescribed in oral formulation and avoid OPAT.
Emergency Department Visit or Inpatient Hospitalization During
Outpatient Parenteral Antimicrobial Therapy

All hospital admissions and ED encounters occurring during
an OPAT episode were identified. The ED count included only
encounters in which the patient was discharged from the ED.
Patients admitted as an inpatient from the ED were only counted
as an inpatient encounter. The same method for diagnostic classification was applied for these ED and inpatient visits during
OPAT episodes. The following ICD-9-CM codes were selected
as diagnoses related to an OPAT complication: (1) infection
due to central venous catheter (99931); (2) mechanical complication of other vascular device, implant, and graft (9961); (3)
other complications due to other vascular device, implant, and
graft (99674); or (4) fever (78060, 78061). Although there are
multiple potential causes of fever unrelated to OPAT, all ED and
hospital admission visits with a ICD-9-CM code for fever were
considered a complication, because when a fever does occur
in a patient with a central catheter, it is standard practice to
obtain a blood culture, which may require an acute care visit
and evaluation.
Data Analysis

We used descriptive statistics to characterize patient demographics, diagnoses, antimicrobials, and ED visits and hospital
admissions during OPAT episodes. We determined the percentage of OPAT episodes that contained highly bioavailable
antimicrobials overall and for selected diagnoses. In addition,
we calculated the percentage of OPAT episodes that resulted in
healthcare use as either a hospital admission or ED visit overall and for each diagnostic category, including those episodes
where healthcare use was related to an OPAT complication.
Categorical variables were described using frequencies and
percentages; continuous variables were described using median
and interquartile range. Any comparisons of categorical variables were made using a χ2 test for association. P values <.05
were considered statistically significant. All analyses were performed by using with SAS 9.3 (SAS Institute, Inc., Cary, North
Carolina). The Children's Mercy Hospital Institutional Review
Board deemed this study exempt.

RESULTS
Patient Characteristics and Diagnosis Associated With Outpatient
Parenteral Antimicrobial Therapy

We identified 3433 distinct OPAT episodes for 2687 patients.
Patient demographics are shown in Table 1. Children less than
1 year of age accounted for a smaller percentage of OPAT than
other age groups (P < .001). Overall, 3118 (91%) of OPAT episodes had a single diagnosis, whereas 315 (9%) had 2 or more.
The most common hospital discharge diagnosis categories associated with OPAT episodes were H/O (18%), GI/GU (17%), CF
(13%), osteoarticular (10%), and pulmonary (10%) (Table 2).
Antimicrobials Prescribed During an Outpatient Parenteral Antimicrobial
Therapy Episode

A total of 4774 antimicrobials were prescribed during the
3433 OPAT episodes. Ceftriaxone (24%) and vancomycin
(20%) were the most commonly prescribed antimicrobials
(Figure 1). Highly bioavailable antimicrobials accounted
for 34% of overall antimicrobials prescribed during OPAT
episodes, including 29% of OPAT episodes classified as
osteoarticular and 31% classified as SSTI. The most frequently prescribed highly bioavailable antimicrobials were
fluconazole (10% overall) and clindamycin (6% overall).
Intravenous fluconazole was most commonly prescribed for
H/O patients and for GI/GU and endovascular infections.
Intravenous clindamycin was most commonly prescribed for
osteoarticular infections and SSTIs.
Healthcare Use During an Outpatient Parenteral Antimicrobial Therapy
Episode

More than one third of children receiving OPAT (n = 1289; 38%)
had either an ED visit or hospitalization during an OPAT episode (Table 3). Hematology/oncology diagnostic category was
associated with the highest percentage of medical care encounters with 28% experiencing an ED visit and 51% having a hospitalization during an OPAT episode. Other categories with high
rates of healthcare encounters were endovascular/endocarditis (27% ED, 24% hospitalization) and GI/GU (24% ED, 30%
hospitalization). Overall, 61% of acute healthcare encounters
during OPAT episodes were likely attributable to a catheter-related complication; this rate was relatively consistent across
diagnostic categories (Table 3). Subanalysis was performed by
including only diagnoses in which oral antimicrobial therapy
would more commonly be considered (osteoarticular, pulmonary, SSTI, URI, renal, or surgical site), and 56% of healthcare
encounters were due to OPAT complications. When applied to
the entire cohort, 23% of OPAT episodes resulted in an ED visit
or hospitalization related to an OPAT complication. Among
children who experienced an OPAT-related complication, 25%
were treated with a highly bioavailable antimicrobial. Of the
791 episodes of OPAT-related inpatient or ED use, 265 (33%)
included ICD-9 code for fever, 276 (35%) included ICD-9 code

for line complication, and 250 (32%) included ICD-9 codes for
both fever and line complication.
DISCUSSION

We examined OPAT use in a large population of pediatric Medicaid enrollees encompassing 12 states. Our results
revealed 3 major findings. First, OPAT is used for children with
a wide spectrum of clinical diagnoses and for the administration of a wide variety of antimicrobial agents, including both
antibacterials and antifungals. Second, a substantial number
of OPAT episodes included highly bioavailable antimicrobials prescribed intravenously that could potentially have been
administered orally. Third, patients receiving OPAT are at high
risk for requiring additional ED and inpatient hospitalizations
during their OPAT episode, and the majority of these healthcare
encounters were likely related to OPAT complications.
Many of our findings corroborate previously reported patterns of OPAT use in children. Osteoarticular, pulmonary,
intra-abdominal, and CNS infections are well recognized as
common indications for pediatric OPAT [1, 8, 16]. Ceftriaxone,
cefazolin, vancomycin, clindamycin, and carbapenems were
identified as commonly prescribed antimicrobials in our cohort,
which is consistent with previously published data [8, 16, 17].
It is noteworthy that we identified fluconazole as the 3rd most
commonly prescribed OPAT agent. Antifungal use in OPAT has
not been well examined, and our data suggest that the use of
antifungal therapy, including highly bioavailable azoles, is common during OPAT, especially for H/O patients. Fluconazole
was also frequently prescribed among those with GI/GU, pulmonary, and CNS disease. Although determining the reasons
for prescribing is beyond the scope of this work, fluconazole is

Table 1. Demographics of Children Prescribed OPAT
Demographics

Total Patients N = 2687 (%)

Gender, %male

1427 (53)

Age, median (IQR)

7 (2, 14)

Age Group
a. Less than 1 year

213 (8)

b. 1–5 years

816 (30)

c. 6–12 years

863 (32)

d. 13+ years

795 (30)

Race/Ethnicity
a. Non-Hispanic White

1467 (55)

b. Non-Hispanic Black

490 (18)

c. Hispanic

221 (8)

d. Other

509 (19)

OPAT Episodes
a. Single episode

2277 (85)

b. Multiple episodes

410 (15)

OPAT episodes, mean (SE)

1.28 (0.02)

Abbreviations: IQR, interquartile range; OPAT, outpatient parenteral antimicrobial therapy; SE, standard error.
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Table 2.

Distribution of Primary Diagnoses Among All OPAT Episodes

Diagnostic Categorya

Prevalence (%),
N = 3433

Most Common Antimicrobials
Prescribed (%)b

Table 2. Continued

Diagnostic Categorya

Prevalence (%),
N = 3433

Most Common Antimicrobials
Prescribed (%)b

Hematology/Oncology (H/O)

615 (17.9)

Ceftriaxone (26)
Fluconaozle (22)
Vancomycin (22)
Acyclovir (12)
Cefepime (11)

Surgical Site

88 (2.6)

Vancomycin (25)
Cefazolin (13)
Ceftriaxone (13)
Nafcillin (8)
Ciprofloxacin (7)

Gastrointestinal/
Genitourinary (GI/GU)

583 (17.0)

Ceftriaxone (20)
Metronidazole (17)
Vancomycin (84)
Fluconazole (13)
Piperacillin/tazobactam (13)

Unknown

12 (0.3)

Ceftriaxone (17)
Gentamicin (17)
Amikacin (8)
Ampicillin/sulbactam (8)
Aztreonam (8)

Cystic Fibrosis (CF)

439 (12.8)

Tobramycin (47)
Ceftazidime (27)
Vancomycin (24)
Meropenem (21)
Cefepime (15)

Other

417 (12.1)

Ceftriaxone (26)
Fluconazole (17)
Vancomycin (14)
Clindamycin (6)
Meropenem (6)

Osteoarticular

346 (10.1)

Ceftriaxone (25)
Vancomycin (24)
Clindamycin (20)
Cefazolin (18)
Nafcillin (5)

Pulmonary

340 (9.9)

Ceftriaxone (32)
Vancomycin (22)
Cefepime (11)
Clindamycin (9)
Fluconazole (9)

Central Nervous System (CNS)

264 (7.7)

Ceftriaxone (38)
Vancomycin (19)
Gentamicin (13)
Fluconazole (8)
Metronidazole (7)

Skin Soft Tissue Infection (SSTI)

256 (7.5)

Vancomycin (29
Ceftriaxone (22)
Clindamycin (14)
Cefazolin (9)
Meropenem (6)

Pathogen

244 (7.1)

Vancomycin (23)
Ceftriaxone (19)
Clindamycin (8)
Cefazolin (7)
Meropenem (6)

Bacteremia

202 (5.9)

Ceftriaxone (23)
Vancomycin (16)
Ampicillin (15)
Gentamicin (13)
Cefepime (8)

Vascular/Endocarditis

168 (4.9)

Vancomycin (30)
Ceftriaxone (23)
Fluconazole (10)
Clindamycin (8)
Gentamicin (7)

Upper Respiratory Infection
(URI)

145 (4.2)

Ceftriaxone (47)
Vancomycin (16)
Cefepime (10)
Fluconazole (8)
Ceftazidime (6)

Urinary Tract Infection (UTI)

134 (3.9)

Ceftriaxone (28)
Cefepime (11)
Gentamicin (10)
Vancomycin (9)
Fluconazole (7)
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Abbreviations: ICD-9, International Classification of Diseases, Ninth Revision; OPAT, outpatient
parenteral antimicrobial therapy.
a
Refer to Supplemental Table 2 for the categorization scheme for diagnostic conditions by ICD-9 code.
b
Bold denotes highly bioavailable.

often used as prophylaxis, and the need for IV administration
requires evaluation given its high bioavailability.
Hematology/oncology patients accounted for the greatest
number of OPAT episodes in our study. This is expected given
the high risk for infections due to underlying immunosuppression; however, this group has rarely been accounted for in
previous OPAT studies. Although OPAT has successfully been
administered to manage febrile neutropenic episodes [18], a
growing body of evidence suggest that oral antibiotics alone or
oral step-down therapy after a short course of IV antimicrobials
is acceptable in low-risk febrile, neutropenic patients [19–21].
The use of highly bioavailable agents for OPAT in children
was relatively common in this study and warrants further scrutiny. For some patients, poor gastrointestinal absorption and

Figure 1. Frequency of antimicrobials prescribed during an outpatient
parenteral antimicrobial therapy episode.

concerns about tolerability or compliance with oral therapy
may necessitate OPAT instead of oral administration. In pediatrics, it is unclear whether OPAT enhances adherence because
drug administration is frequently parent or caregiver dependent. Although we were unable to determine the presence of
comorbid conditions that might limit absorption in our study
population, a substantial amount of OPAT use involved agents
such as clindamycin and cefazolin for treatment of osteoarticular infections and SSTI, which are common among otherwise healthy children. The failure to switch from OPAT to oral
administration when using highly bioavailable agents can result
in higher medical care cost and the potential for harm without
evidence of therapeutic benefit [22–24]. Conversion to peroral
antimicrobials could potentially reduce OPAT-related complications because 1 in 4 antimicrobials prescribed in cases with
complications were deemed highly bioavailable.
The benefits of OPAT have traditionally been viewed as outweighing the risks when used to treat infections presumably
requiring IV therapy. However, recent evidence suggests that the
effectiveness of oral therapy is comparable to OPAT after hospital

Table 3.

discharge for conditions such as acute osteoarticular infections and
perforated appendicitis with fewer complications due to avoidance
of central catheters [22, 25–27]. Because of the high cost and potential for complications, additional studies are needed to compare the
effectiveness of OPAT to oral therapy for other conditions as well as
comparisons between longer and shorter durations of IV therapy.
Previous studies have highlighted that OPAT complications
occur frequently, approaching 30% in some reports [11, 28].
This is consistent with our findings in which over 20% of OPAT
episodes resulted in children requiring medical care in the hospital or ED setting for an OPAT complication. Outpatient parenteral antimicrobial therapy use in pediatrics may not routinely
be monitored by infectious diseases specialists or stewardship
programs, and recent studies indicate that a substantial percentage of pediatric OPAT is potentially avoidable [17, 29, 30]. The
expansion of pediatric antimicrobial stewardship programs to
encompass OPAT is a promising strategy to improve the safety
and appropriateness of OPAT use. The integration of stewardship principles into clinical decision making prior to OPAT initiation is critical [31]. A proposed OPAT bundle to assure that

Percentage of OPAT Episodes Involving at Least One Emergency Department Visit or Hospital Admission
Overall ED Utilization
by Children Receiving
OPAT (%)

ED Utilization With OPAT
Complicationb (%)

Overall Inpatient Utilization
by Children Receiving
OPAT (%)

Inpatient Utilization With
OPAT Complicationb (%)

Hematology/Oncology
(H/O), N = 615

174 (28)

94 (54)

311 (51)

236 (76)

368 (60)

274 (75)

Gastrointestinal/
Genitourinary (GI/GU),
N = 583

140 (24)

71 (51)

172 (30)

119 (69)

242 (42)

153 (63)

Diagnostic Catergorya

Cystic Fibrosis (CF), N = 439
Other, N = 417

Overall Inpatient or ED
Utilization by Children
Receiving OPAT (%)

Inpatient or ED Utilization
With OPAT Complicationb
(%)

44 (10)

14 (32)

57 (13)

17 (30)

88 (20)

31 (35)

125 (30)

61 (49)

112 (27)

65 (58)

182 (44)

104 (57)

Osteoarticular, N = 346

66 (19)

38 (58)

38 (11)

22 (58)

90 (26)

57 (63)

Pulmonary, N = 340

79 (23)

37 (47)

66 (19)

34 (52)

117 (34)

63 (54)

Central Nervous System
(CNS), N = 264

57 (22)

24 (42)

49 (19)

28 (57)

88 (3)

46 (52)

Skin Soft Tissue Infection
(SSTI), N = 256

45 (18)

17 (38)

30 (12)

15 (50)

66 (26)

31 (47)

Pathogen, N = 244

50 (21)

24 (48)

38 (16)

23 (61)

78 (32)

45 (58)

Bacteremia, N = 202

28 (14)

14 (50)

26 (13)

18 (69)

45 (22)

28 (62)

Vascular/Endocarditis,
N = 168

45 (27)

30 (67)

41 (24)

24 (59)

72 (43)

46 (64)

Upper Respiratory Infection
(URI), N = 145

38 (26)

22 (58)

17 (12)

9 (53)

45 (31)

26 (58)

Renal, N = 134

28 (21)

12 (43)

29 (22)

16 (55)

45 (34)

22 (49)

Surgical Site, N = 88

17 (19)

9 (53)

9 (10)

5 (56)

24 (27)

13 (54)

Unkown, N = 12

1 (8)

1 (100)

1 (8)

1 (100)

1 (8)

1 (100)

Diagnoses limited to osteoarticular, pulmonary,
SSTI, URI, renal or surgical site onlyc N = 978

209 (21)

105 (50)

149 (15)

82 (55)

297 (30)

167 (56)

Overall (all diagnoses),
N = 3433

776 (23)

387 (50)

852 (25)

549 (64)

1,289 (38)

791 (61)

Abbreviations: ED, emergency department; ICD-9-CM, International Classification of Diseases, Ninth Revision, Clinical Modification; OPAT, outpatient parenteral antimicrobial therapy.
a
Diagnostic categories are not mutually exclusive; OPAT episodes may be counted in more than 1 diagnostic category.
b
The following ICD-9-CM codes were selected as diagnoses related to an OPAT complication: (1) infection due to central venous catheter (99931); (2) mechanical complication of other vascular device, implant, and graft (9961); (3)
other complications due to other vascular device, implant, and graft (99674); or (4) fever (78060, 78061).
c
Diagnoses were mutually exclusive; only included OPAT episodes with a single diagnosis.
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patient selection, Infectious Diseases consultation, patient/caregiver education, and tracking of outcomes has been suggested
to enhance safety practices surrounding OPAT [32]. Recognized
clinical characteristics can further be used to identify those at
highest risk to prevent OPAT-related hospital admissions [13].
Our study has several limitations. We used Medicaid data
from 12 anonymous states, and our findings may not be generalizable to other US regions or commercially insured children.
Because the database does not provide the total population of
Medicaid enrollees, we were unable to determine the population-based incidence of OPAT. We used a conservative approach
to define OPAT requiring both a HIT HCPCS code indicating
HIT and concomitant code for antimicrobial use or retail pharmacy fill for an IV antimicrobial, and this could have resulted
in an underestimation of the number of children prescribed
OPAT. A HIT episode did not confirm the duration of IV antibiotic therapy administered; therefore, we were unable to make
a conclusion about the impact of duration on OPAT complications. Because we were unable to review the medical charts for
each OPAT episode, we may have misclassified the indication for
OPAT or the reasons for subsequent healthcare use, and we were
unable to determine the appropriateness of OPAT. Complication
rates did vary by diagnostic category with H/O having the
highest rate. When excluding diagnoses such as H/O and only
evaluating diagnoses in which enteral administration of an antimicrobial is more commonly considered, the ED visit or hospitalization attributable to an OPAT complication rate remained
high. Although we could have overestimated the complication
rate by including fever, the majority of complications were associated with ICD-9-CM codes specific to a line complication.
CONCLUSIONS

Outpatient parenteral antimicrobial therapy frequently contains
highly bioavailable antimicrobials that in some cases could be
used orally, and more than 1 in 5 children treated with OPAT
experience unanticipated ED visits or hospitalizations for OPAT
complications. Because OPAT is prescribed for a broad range of
diagnoses, pediatric specialists, including gastroenterologists,
oncologists, surgeons, hospitalists, and infectious diseases physicians, must be aware of the complication risk when prescribing OPAT, especially when highly bioavailable options exist.
Broadening the scope of pediatric stewardship programs to
encompass hospital discharge planning for antimicrobial therapy
has the potential to improve the quality and safety of OPAT use.
Supplementary Data
Supplementary materials are available at Journal of the Pediatric Infectious
Diseases Society online.
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